Skip to content

Preliminary Establishment of the Medical Reference Range of Serum Vitamin K2 in Chinese Healthy Adults

Preliminary Establishment of the Medical Reference Range of Serum Vitamin K2 in Chinese Healthy Adults

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05436483
Enrollment
465
Registered
2022-06-29
Start date
2022-07-31
Completion date
2023-08-31
Last updated
2022-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health, Subjective

Brief summary

Osteocalcin is a type of vitamin K2-dependent protein, and many studies have confirmed that vitamin K2 has anti-osteoporosis effects, and has preventive and therapeutic effects on a variety of diseases such as nervous system, cardiovascular disease, immune disease, and glucose metabolism. However, as a pleiotropic vitamin and nutrient, vitamin K2 does not have an exact normal range like other vitamins, when it needs to be supplemented, and in what regimen. Different organizations have different opinions on the recommended intake of vitamin K. Thus, this study intends to preliminarily obtain the reference interval of serum vitamin K2 by conducting clinical research in healthy people in the Beijing-Tianjin-Hebei region, and analyzes different factors, such as gender, age, and place of residence, to compare their level differences and changing trends, and to provide data reference for the recommended intake of vitamin K2 for people with vitamin K2 deficiency.

Interventions

None listed

Sponsors

Peking University Third Hospital
Lead SponsorOTHER

Study design

Observational model
ECOLOGIC_OR_COMMUNITY
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
Yes

Inclusion criteria

* People aged over 18. * People with normal routine blood test. * Willing to participate in this study.

Exclusion criteria

* Subjects with congenital metabolic problems and endocrine diseases. * Treatment with any investigational drug within the past 3 months.

Design outcomes

Primary

MeasureTime frameDescription
Concentration of vitamin K2During the procedure of regular physical checkupsVitamin K2 concentration in serum

Contacts

Primary ContactQi Liu, Ph. D.
liuqicpu@hotmail.com+8615501060136
Backup ContactChunli Song, M.D.; Ph. D.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026